Your browser doesn't support javascript.
loading
Antagonism of proNGF or its receptor p75NTR reverses remodelling and improves bladder function in a mouse model of diabetic voiding dysfunction.
Mossa, Abubakr H; Galan, Alba; Cammisotto, Philippe G; Velasquez Flores, Monica; Shamout, Samer; Barcelona, Pablo; Saragovi, H Uri; Campeau, Lysanne.
Afiliação
  • Mossa AH; Lady Davis Research Institute, McGill University, 3755 Chemin de la Cote-Ste-Catherine, Montreal, QC, H3T 1E2, Canada.
  • Galan A; Lady Davis Research Institute, McGill University, 3755 Chemin de la Cote-Ste-Catherine, Montreal, QC, H3T 1E2, Canada.
  • Cammisotto PG; Lady Davis Research Institute, McGill University, 3755 Chemin de la Cote-Ste-Catherine, Montreal, QC, H3T 1E2, Canada.
  • Velasquez Flores M; Lady Davis Research Institute, McGill University, 3755 Chemin de la Cote-Ste-Catherine, Montreal, QC, H3T 1E2, Canada.
  • Shamout S; Lady Davis Research Institute, McGill University, 3755 Chemin de la Cote-Ste-Catherine, Montreal, QC, H3T 1E2, Canada.
  • Barcelona P; Division of Urology, Department, of Surgery, McGill University, Montreal, QC, Canada.
  • Saragovi HU; Lady Davis Research Institute, McGill University, 3755 Chemin de la Cote-Ste-Catherine, Montreal, QC, H3T 1E2, Canada.
  • Campeau L; Lady Davis Research Institute, McGill University, 3755 Chemin de la Cote-Ste-Catherine, Montreal, QC, H3T 1E2, Canada.
Diabetologia ; 63(9): 1932-1946, 2020 09.
Article em En | MEDLINE | ID: mdl-32699962
AIMS/HYPOTHESIS: Although 80% of diabetic patients will suffer from voiding difficulties and urinary symptoms, defined as diabetic voiding dysfunction (DVD), therapeutic targets and treatment options are limited. We hypothesise that the blockade of the pro-nerve growth factor (NGF)/p75 neurotrophin receptor (p75NTR) axis by an anti-proNGF monoclonal antibody or by a small molecule p75NTR antagonist (THX-B) can restore bladder remodelling (represented by bladder weight) in an animal model of DVD. Secondary outcomes of the study include improvements in bladder compliance, contractility and morphology, as well as in voiding behaviour, proNGF/NGF balance and TNF-α expression. METHODS: In a streptozotocin-induced mouse model of diabetes, diabetic mice received either a blocking anti-proNGF monoclonal antibody or a p75NTR antagonist small molecule as weekly systemic injections for 4 weeks. Animals were tested at baseline (at 2 weeks of diabetes induction), and after 2 and 4 weeks of treatment. Outcomes measured were voiding function with voiding spot assays and cystometry. Bladders were assessed by histological, contractility and protein expression assays. RESULTS: Diabetic mice showed features of DVD as early as 2 weeks after diabetes diagnosis (baseline) presented by hypertrophy, reduced contractility and abnormal cystometric parameters. Following treatment initiation, a twofold increase (p < 0.05) in untreated diabetic mouse bladder weight and thickness compared with non-diabetic controls was observed, and this change was reversed by p75NTR antagonism (37% reduction in bladder weight compared with untreated diabetic mice [95% CI 14%, 60%]) after 4 weeks of treatment. However, blocking proNGF did not help to reverse bladder hypertrophy. While diabetic mice had significantly worse cystometric parameters and contractile responses than non-diabetic controls, proNGF antagonism normalised bladder compliance (0.007 [Q1-Q3; 0.006-0.009] vs 0.015 [Q1-Q3; 0.014-0.029] ml/cmH2O in untreated diabetic mice, representing 62% reduction [95% CI 8%, 110%], p < 0.05) and contractility to KCl, carbachol and electrical field stimulation (p < 0.05 compared with the diabetic group) after 2 weeks of treatment. These effects were not observed after 4 weeks of treatment with proNGF antagonist. p75NTR antagonism did not show important improvements in cystometric parameters after 2 weeks of treatment. Slightly improved bladder compliance (0.01 [Q1-Q3; 0.009-0.012] vs 0.013 [Q1-Q3; 0.011-0.016] ml/cmH2O for untreated diabetic mice) was seen in the p75NTR antagonist-treated group after 4 weeks of treatment with significantly stabilised contractile responses to KCl, carbachol and electric field stimulation (p < 0.05 for each) compared with diabetic mice. Bladder dysfunction observed in diabetic mice was associated with a significant increase in bladder proNGF/NGF ratio (3.1 [±1.2] vs 0.26 [±0.04] ng/pg in control group, p < 0.05 at week 2 of treatment) and TNF-α (p < 0.05). The proNGF/NGF ratio was partially reduced (about 60% reduction) with both treatments (1.03 [±0.6] ng/pg for proNGF antibody-treated group and 1.4 [±0.76] ng/pg for p75NTR blocker-treated group after 2 weeks of treatment), concomitant with a significant decrease in the bladder levels of TNF-α (p < 0.05), despite persistent hyperglycaemia. CONCLUSIONS/INTERPRETATION: Our findings indicate that blockade of proNGF and the p75NTR receptor in diabetes can impede the development and progression of DVD. The reported improvements in morphological and functional features in our DVD model validates the proNGF/p75NTR axis as a potential therapeutic target in this pathology. Graphical abstract.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Precursores de Proteínas / Transtornos Urinários / Bexiga Urinária / Receptores de Fator de Crescimento Neural / Fator de Crescimento Neural / Complicações do Diabetes / Diabetes Mellitus Experimental Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Diabetologia Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Precursores de Proteínas / Transtornos Urinários / Bexiga Urinária / Receptores de Fator de Crescimento Neural / Fator de Crescimento Neural / Complicações do Diabetes / Diabetes Mellitus Experimental Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Diabetologia Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá